GSK seeks EU marketing approval for lupus drug

Says to seek U.S. FDA approval by end June

Wednesday, June 9, 2010

GlaxoSmithKline Plc has sought European regulators' marketing approval for its experimental lupus drug Benlysta, being developed along with Human Genome Sciences Inc, the companies said.